VodurSureshReddyMD

Hematology • Reno, NV

Myeloproliferative Disorder Hematology-Oncology

Physician

Join to view full profile

Are you Dr. Reddy?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 46 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
5423 Reno Corporate Dr
Reno, NV 89511
Phone+1 775-329-0873

Fax+1 775-329-1026

Summary

Dr. Vodur Reddy, MD is a hematologist in Reno, Nevada. He is currently licensed to practice medicine in Nevada, Florida, and Georgia. He is affiliated with Renown Regional Medical Center and Carson Tahoe Health.

Education & Training

University of FloridaResidency, Internal Medicine, 1996 - 1999
University of Missouri-Columbia School of MedicineClass of 1996

Certifications & Licensure

NV State Medical License 2002 - 2025
FL State Medical License 2004 - 2006
GA State Medical License 1998 - 2003
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery Start of enrollment: 2010 Mar 01
Terminated
Phase 3
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Start of enrollment: 2010 Feb 15
Completed
Phase 3
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Jul 08
Completed
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

5 citations
Multiple myeloma remission following COVID-19: an observation in search of a mechanism (a case report).
Daniel Antwi-Amoabeng, Mark B. Ulanja, Bryce D Beutler, Suresh Vodur Reddy
The Pan African Medical Journal. 2021-06-10
3 citations
Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the ALK Gene Have Durable Responses to ALK Kinase Inhibitors
Alexa B. Schrock, Russell Madison, Margaret Rosenzweig, Justin M. Allen, Rachel L. Erlich
Lung Cancer. 2020-04-17